Publications

Group highlights

(For a full list of publications and patents see below or go to Google Scholar)

IL-2 is inactivated by the acidic pH environment of tumors enabling engineering of a pH-selective mutein

Cytokines are extremely sensitive to the acidic pH found in tumors and lymph nodes. The activity of IL-2, a cytokine central to T cell responses, is highly limited at acidic pH. Using in vitro evolution, a new IL-2 variant, Switch-2, was developped. It exhibits enhanced activity at acidic pH but, exhibits reduced activity at the neutral pH found in healthy tissue. Switch-2 therapy in mice triggered potent antitumor responses while avoiding the severe systemic toxicity associated with IL-2 therapies.

Gaggero S, Martinez-Fabregas J, Cozzani A, Fyfe PK, Leprohon M, Yang J, Thomasen FE, Winkelmann H, Magnez R, Conti AG, Wilmes S, Pohler E, van Gijsel Bonnello M, Thuru X, Quesnel B, Soncin F, Piehler J, Lindorff-Larsen K, Roychoudhuri R, Moraga I, Mitra S.

Sci. Immunol.7,eade5686(2022).

CDK8 fine-tunes IL-6 transcriptional activities by limiting STAT3 resident time at the gene loci.

CDK8 represses IL-6-mediated transcription by limiting STAT3 resident time at the gene loci. By regulating CDK8 expression levels, immune cells can adapt their responses to STAT3-activating cytokines.

Martinez F. J, Wang L, Pohler E, Lokau J, Garbers C, Cozzani A, Kazemian M, Mitra S, Moraga I.

Cell Reports, 2020 3 3 (12)

Universal toxin-based selection for precise genome engineering in human cells.

This work presents a flexible, precise, and efficient selection strategy to engineer cells using CRISPR-Cas and base editing systems. The method enables the rapid generation of a homogenous cell population with bi-allelic integration of a DNA casette at the selection locus, without clonal isolation.

Li S, Akrap N, Cerboni S, Porritt M, Wimberger S, Lundin A, Möller C, Firth M, Gordon E, Lazovic B, Sienska A, Simona Pene L, Coelho M, Ciotta G, Pellegrini G, Sini M, Xu X, Mitra S, Bohlooly-Y M, Taylor B, Sienski G, and  Maresca M.

Nature Communications, 12, 497, 2021

Cytokine‐regulated Th17 plasticity in human health and diseases.

A review about how cytokines regulate intracellular networks and control human Th17 plasticity. We discuss the importantance of Th17 plasticity in autoimmunity and cancer and present current strategies and challenges in targeting pathogenic Th17 cells with cytokines-based approaches.

Cerboni S, Gehrmann U, Preite S, Mitra S.

Immunology, 163, 1, 2021

Cytokines orchestrating the NK-myeloid cell crosstalk in the tumor microenvironment: Implications for NK cell-based cancer immunotherapy.

A review about the complex functions of myeloid-derived cytokines in both supporting and suppresing natural killer (NK) cells in the tumor microenvironment (TME). We present strategies using pathways involved in the NK-myeloid cell crosstalk in the TME to improve NK cell-base immunotherapies.

Gaggero S, Witt K, Carlsten M# and Mitra S

Frontiers of Immunology, 11:621225 2021

LDH Inhibition and IL-21 Synergistically Promote CD8+ T Stemness and Antitumor Immunity.

LDH inhibition enhanced the generation of memory cells capable of triggering robust antitumor responses after adoptive transfer. Combined with IL-21, LDH inhibition resulted in more profound antitumor responses and prolonged host survival. This underscores the therapeutic potential of transiently inhibiting LDH during adoptive T cell-base immunotherapy, with an unanticipated cooperative anti-tumor effect of LDH inhibition and IL-21.

Hermans D, Gautam S, García-Cañaveras JC, Gromer D, Mitra S, Spolski R1, Li P, Christensen S, Lin JX, Oh J, Du N, Veenbergen S, Fioravanti J, Ebina-Shibuya R, Bleck C, Neckers LM, Rabinowitz JD, Gattinoni L, Leonard WJ

PNAS, 2020 117 (11) 6047-6055

The 11q13.5 immune disease risk locus contains a distal enhancer required for Treg-mediated suppression of gut inflammation.

The functions of a vast majority of disease-associated enhancers are unresolved. This work provides a mechanistic basis for association of the 11q13.5 risk locus with immune-mediated diseases and identify GARP as a potential target in their therapy.

Nasrallah R, Grant FM, Bossini-Castill L, Imianowski CJ, Sadiyah F, Mumbach MR, Glinos D, Vardaka P, Lozan T, Fujii H, , Yang J, Andrews S, Mitra S, Unutmaz D, Lugli E Trynka G and Roychoudhuri R

Nature volume 583, pages 447–452 (2020)

Molecular profiling of driver events and tumor-infiltrating lymphocytes in metastatic uveal melanoma

This work presents a large whole-genome analysis of metastatic uveal melanoma. It highlights the role of BAP1 alteration as a riving event for uveal melanoma progression. Transcriptomic analysis showed a high expression of immune checkpoint receptors TIM-3, TIGIT and LAG3 in Tumor-infiltrating lymphocytes.

Karlsson J, Nilsson LM, Mitra S, Alsén S, Shelke G, Sah VR, Stierner U, Forsberg EV, All-Eriksson C, Einarsdottir B, Jespersen H, Ny L, Lindnér P, Larsson E, Bagge RO, Nilsson JA

Nature Communications volume 11, 1894 (2020)

Kinetics of cytokine receptor trafficking determine signaling and functional selectivity

Cytokines activate signaling via assembly of cell surface receptors. Engineered IL-6 variants with different affinities to gp130 induced biased signaling, with changes in receptor binding dwell-times affecting more profoundly STAT1 than STAT3 phosphorylation. This demonstrate that manipulation of signaling thresholds is a useful strategy to decouple cytokine functional pleiotropy.

Martinez F. J, Wilmes S, Wang L, Hafer M, Pohler E, Lokau J, Garbers C, Cozzani A, Piehler J, Kazeman M, Mitra S, Moraga I

eLife 2019 8;e49314

 

Patents

Super agonists, Partial Agonists and Antagonists of Interleukin-2
Patent no: WO2015164815A1.
Suman Mitra, co-inventor

Methods of treating graft versus host disease with an IL-2 meutin
US-10654905-B2.
Suman Mitra, co-inventor

Novel IL-10 agonists for application in immunotherapy
PE960351(GB).
Suman Mitra, co-inventor

Full List of publications

IL-2 is inactivated by the acidic pH environment of tumors enabling engineering of a pH-selective mutein
Gaggero S, Martinez-Fabregas J, Cozzani A, Fyfe PK, Leprohon M, Yang J, Thomasen FE, Winkelmann H, Magnez R, Conti AG, Wilmes S, Pohler E, van Gijsel Bonnello M, Thuru X, Quesnel B, Soncin F, Piehler J, Lindorff-Larsen K, Roychoudhuri R, Moraga I, Mitra S.
Sci. Immunol.7,eade5686(2022).

CDK8 fine-tunes IL-6 transcriptional activities by limiting STAT3 resident time at the gene loci.
Martinez F. J, Wang L, Pohler E, Lokau J, Garbers C, Cozzani A, Kazemian M, Mitra S, Moraga I.
Cell Reports, 2020 3 3 (12)

Universal toxin-based selection for precise genome engineering in human cells.
Li S, Akrap N, Cerboni S, Porritt M, Wimberger S, Lundin A, Möller C, Firth M, Gordon E, Lazovic B, Sienska A, Simona Pene L, Coelho M, Ciotta G, Pellegrini G, Sini M, Xu X, Mitra S, Bohlooly-Y M, Taylor B, Sienski G, and  Maresca M.
Nature Communications, 12, 497, 2021

Cytokine‐regulated Th17 plasticity in human health and diseases.
Cerboni S, Gehrmann U, Preite S, Mitra S.
Immunology, 163, 1, 2021

Cytokines orchestrating the NK-myeloid cell crosstalk in the tumor microenvironment: Implications for NK cell-based cancer immunotherapy.
Gaggero S, Witt K, Carlsten M# and Mitra S
Frontiers of Immunology, 11:621225 2021

LDH Inhibition and IL-21 Synergistically Promote CD8+ T Stemness and Antitumor Immunity.
Hermans D, Gautam S, García-Cañaveras JC, Gromer D, Mitra S, Spolski R1, Li P, Christensen S, Lin JX, Oh J, Du N, Veenbergen S, Fioravanti J, Ebina-Shibuya R, Bleck C, Neckers LM, Rabinowitz JD, Gattinoni L, Leonard WJ
PNAS, 2020 117 (11) 6047-6055

The 11q13.5 immune disease risk locus contains a distal enhancer required for Treg-mediated suppression of gut inflammation.
Nasrallah R, Grant FM, Bossini-Castill L, Imianowski CJ, Sadiyah F, Mumbach MR, Glinos D, Vardaka P, Lozan T, Fujii H, , Yang J, Andrews S, Mitra S, Unutmaz D, Lugli E Trynka G and Roychoudhuri R
Nature volume 583, pages 447–452 (2020)

Molecular profiling of driver events and tumor-infiltrating lymphocytes in metastatic uveal melanoma
Karlsson J, Nilsson LM, Mitra S, Alsén S, Shelke G, Sah VR, Stierner U, Forsberg EV, All-Eriksson C, Einarsdottir B, Jespersen H, Ny L, Lindnér P, Larsson E, Bagge RO, Nilsson JA
Nature Communications volume 11, 1894 (2020)

Kinetics of cytokine receptor trafficking determine signaling and functional selectivity
Martinez F. J, Wilmes S, Wang L, Hafer M, Pohler E, Lokau J, Garbers C, Cozzani A, Piehler J, Kazeman M, Mitra S, Moraga I
eLife 2019 8;e49314

STAT5-mediated chromatin interactions in super-enhancers activate IL-2 highly inducible genes: Functional dissection of the Il2ra gene locus.
Li P, Mitra S, Spolski R, Oh J, Liao W, Tang Z, Mo F, Li X, West EE, Gromer D, Lin JX, Liu C, Ruan Y, Leonard WJ
PNAS November 14, 2017 114 (46)

Interleukin-2 activity can be fine-tuned with engineered receptor signaling clamps.
Mitra S, Ring AM, Amarnath S, Spangler JB, Li P, Ju W, Fischer S, Oh J, Spolski R, Weiskopf K, Kohrt H, Foley JE, Rajagopalan S, Long EO, Fowler DH, Waldmann TA, Garcia KC, Leonard WJ
Immunity. 2015 May 19; 42(5).